Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
Carole A. Spencer,M Takeuchi,M. Kazarosyan,C. C. Wang,Richard B. Guttler,Peter Singer,Shireen Fatemi,Jonathan S. LoPresti,John T. Nicoloff +8 more
Reads0
Chats0
TLDR
The RIA method used in this study provided more clinically appropriate serum Tg values in the group of TgAb-positive patients with metastatic DTC and may be an additional clinically useful tumor marker parameter for following T gAb- positive patients.Abstract:
The prevalence of circulating thyroid autoantibodies (TgAb or antithyroid peroxidase) was increased nearly 3-fold in patients with differentiated thyroid cancers (DTC) compared with the general population (40% vs. 14%, respectively). Serum TgAb (with or without antithyroid peroxidase) was present in 25% of DTC patients and 10% of the general population. Serial postsurgical serum TgAb and serum Tg patterns correlated with the presence or absence of disease. Measurements of serum Tg were made in 87 TgAb-positive sera by a RIA and two immunometric assay (IMA) methods to study TgAb interference. TgAb interference, defined as a significant intermethod discordance (>41.7% coefficient of variation) between the Tg RIA and Tg IMA values relative to TgAb-negative sera, was found in 69% of the TgAb-positive sera. TgAb interference was characterized by higher Tg RIA vs. IMA values and was, in general, more frequent and severe in sera containing high TgAb concentrations. However, some sera displayed marked interference when serum TgAb was low (1-2 IU/mL), whereas other sera with very high TgAb values (>1000 IU/mL) displayed no interference. An agglutination method was found to be too insensitive to detect low TgAb concentrations (1-10 IU/mL) causing interference. Exogenous Tg recovery tests were an unreliable means for detecting TgAb interference. Specifically, the exogenous Tg recovered varied with the type and amount of Tg added and the duration of incubation employed. Further, recoveries of more than 80% were found for some sera displaying gross serum RIA/IMA discordances. The measurement of serum Tg in DTC patients with circulating TgAb is currently problematic. It is important to use a Tg method that provides measurements that are concordant with tumor status. IMA methods are prone to underestimate serum when TgAb is present, increasing the risk that persistent or metastatic DTC will be missed. The RIA method used in this study provided more clinically appropriate serum Tg values in the group of TgAb-positive patients with metastatic DTC. Furthermore, as serial serum TgAb measurements paralleled serial serum Tg RIA measurements, TgAb concentrations may be an additional clinically useful tumor marker parameter for following TgAb-positive patients. Disparities between serial serum Tg and TgAb measurements might alert the physician to the possibility of TgAb interference with the serum Tg measurement and prompt a more cautious use of such data for clinical decision-making.read more
Citations
More filters
Journal ArticleDOI
The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid Carcinoma
Steven G. Waguespack,Steven I. Sherman,Michelle D. Williams,Gary L. Clayman,Cynthia E. Herzog +4 more
TL;DR: In the very rare case of the pediatric patient with progressive RAI-refractory PTC, for which no good systemic therapy exists, sorafenib may play an important role in the management of this disease.
Journal ArticleDOI
Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience.
H.M. van Santen,Doron Aronson,T. Vulsma,R.F.H.M Tummers,M.M. Geenen,J. J. M. De Vijlder,C. van den Bos +6 more
TL;DR: The aim was to analyse early and late adverse events in childhood differentiated thyroid carcinoma patients treated between 1962 and 2002 and emphasise the need to improve treatment strategies.
Journal ArticleDOI
Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance
Pedro Weslley Rosario,Frederico F.R. Maia,Tales Alvarenga Fagundes,Flávio P.J. Vasconcelos,Ludmilla David Cardoso,Saulo Purisch +5 more
TL;DR: TgAb should be determined by immunoassays; interference with Tg measurements occurred mainly but not always at high concentrations, with a normal Tg recovery test not excluding this interference.
Journal ArticleDOI
Laboratory Tests of Thyroid Function: Uses and Limitations
TL;DR: The common methods of laboratory testing relating to thyroid disease are summarized and specific information for individual tests on methods of analysis, their limitations, and situations where caution should be used in interpreting the results of thyroid tests are discussed.
Journal ArticleDOI
Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study.
Rocco Bellantone,Celestino Pio Lombardi,Maurizio Bossola,Angela Ferrante,Pietro Princi,Mauro Boscherini,Ludovica Maussier,Massimo Salvatori,Vittoria Rufini,Francesca Reale,Luisa Romano,Giovanni Tallini,Giovanni Zelano,Alfredo Pontecorvi +13 more
TL;DR: The objective of the current study was to evaluate the ability of serum thyroglobulin mRNA assay in detecting local and distant recurrences in patients who underwent surgery for thyroid carcinoma.
References
More filters
Journal ArticleDOI
Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma
M. Schlumberger,M. Tubiana,F. de Vathaire,Catherine Hill,P. Gardet,Jean-Paul Travagli,Philippe Fragu,Jean Lumbroso,Bernard Caillou,Claude Parmentier +9 more
TL;DR: The results suggest that the aim of management should be to detect and treat metastases in patients with thyroid cancer as early as possible.
Journal ArticleDOI
Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.
A J Herle,R P Uller +1 more
TL;DR: The data support the thesis that in differentiated thyroid carcinoma serum thyroglobulin levels are elevated when metastases develop after initial treatment and represent a simple and valuable adjunct in the posttreatment follow up of patients with differentiated thyroid cancer.
Journal ArticleDOI
Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls.
TL;DR: Physicians need to consider a number of factors before selecting a laboratory to perform Tg measurements in patients with differentiated thyroid carcinoma, including assay sensitivity, as judged by the discrimination between lower limit of the euthyroid range and the functional sensitivity limit, as well as assay specificity, especially with respect to serum TgAb interference.
Journal ArticleDOI
The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland
Sunao Matsubayashi,Keisuke Kawai,Y. Matsumoto,T. Mukuta,Tetsuya Morita,K Hirai,Fumio Matsuzuka,K.-I. Kakudoh,Kanji Kuma,Hajime Tamai +9 more
TL;DR: Lymphocytic infiltration surrounding the tumor or inside the tumor in PTC might be of use as a means for predicting a favorable prognosis and class II or class III patients with no lymphocytic infiltrate had a high rate of recurrence.
Journal ArticleDOI
Current status and performance goals for serum thyroglobulin assays.
TL;DR: Optimal performance goals are recommended for manufacturers developing and laboratories and physicians selecting a serum Tg method to use for serial long-term monitoring of thyroid cancer patients.
Related Papers (5)
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
Bryan R. Haugen,Furio Pacini,Christoph Reiners,Martin Schlumberger,Paul W. Ladenson,Steven I. Sherman,David S. Cooper,Kathryn E. Graham,Lewis E. Braverman,Monica C. Skarulis,Terry F. Davies,Leslie J. DeGroot,Ernest L. Mazzaferri,Gilbert H. Daniels,Douglas S. Ross,Markus Luster,Mary H. Samuels,David V. Becker,Harry R. Maxon,Ralph R. Cavalieri,Carole A. Spencer,Kevin McEllin,Bruce D. Weintraub,E. Chester Ridgway +23 more